Precision Medicine in Oncology

Latest Content


Patients with advanced pancreatic cancer linked to germline genetic mutations did not see their disease worsen for an additional 3.6 months when treated with olaparib, but an early interim analysis did not show a statistically significant difference in overall survival (OS), according to study results presented Sunday at the American Society of Clinical Oncology Annual Meeting 2019.

Testing for minimal residual disease (MRD) is increasingly being used in patients with cancer because deep MRD negativity is associated with better outcomes for patients and MRD status can help make decisions regarding treatment. Two abstracts presented at the 2019 American Society of Clinical Oncology Annual Meeting validated use of MRD testing in the real world and found it was cost-effective.

Things like smoking, poor diet, and lack of exercise can increase a person’s risk of developing cancer, but there are some things that are actually more clinically acute outside of family history that every patient needs to look out for, explained Feyi Olopade Ayodele, MBA, chief executive officer at CancerIQ.

In oncology, precision medicine is already well established with targeted therapies approved based on the patient’s genetic makeup or genetic variants of their tumor, and using precision medicine successfully means also using diagnostics and next-generation sequencing (NGS). Last year, CMS finalized coverage of NGS tests, which are to be used to identify patients that may benefit the most from approved treatments. And it looks like other payers may be following CMS’ lead.

Healthcare is very comfortable with treating a disease, but it’s not as good with handling cures. However, the advent of gene therapy and precision medicine means more and more expensive cures are coming down the pipeline, said panelists on the last day of Asembia’s 15th annual Specialty Pharmacy Summit, held April 29 to May 2 in Las Vegas, Nevada.

The treatment of lung cancer with personalized medicine has come a long way in recent decades, but still more achievements remain to be seen, said Bruce Johnson, MD, FASCO, immediate past president of the American Society of Clinical Oncology, during his keynote speech opening the Business of Oncology Summit hosted by the Florida Society of Clinical Oncology in Kissimmee, Florida.